JP6223338B2 - 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 - Google Patents
活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 Download PDFInfo
- Publication number
- JP6223338B2 JP6223338B2 JP2014525943A JP2014525943A JP6223338B2 JP 6223338 B2 JP6223338 B2 JP 6223338B2 JP 2014525943 A JP2014525943 A JP 2014525943A JP 2014525943 A JP2014525943 A JP 2014525943A JP 6223338 B2 JP6223338 B2 JP 6223338B2
- Authority
- JP
- Japan
- Prior art keywords
- tnfr
- fusion protein
- buffer
- protein
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010008165 Etanercept Proteins 0.000 title claims description 91
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 52
- 239000000872 buffer Substances 0.000 claims description 39
- 239000001509 sodium citrate Substances 0.000 claims description 31
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 26
- 239000001488 sodium phosphate Substances 0.000 claims description 25
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 25
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 239000006167 equilibration buffer Substances 0.000 claims description 19
- 239000012149 elution buffer Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 239000011534 wash buffer Substances 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000011033 desalting Methods 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 116
- 102000004169 proteins and genes Human genes 0.000 description 101
- 235000018102 proteins Nutrition 0.000 description 93
- 108020001507 fusion proteins Proteins 0.000 description 34
- 102000037865 fusion proteins Human genes 0.000 description 33
- 239000000523 sample Substances 0.000 description 31
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 27
- 235000011152 sodium sulphate Nutrition 0.000 description 27
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 26
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 14
- 102000005396 glutamine synthetase Human genes 0.000 description 14
- 108020002326 glutamine synthetase Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000012266 salt solution Substances 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 10
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 238000011067 equilibration Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 101150074355 GS gene Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000011548 crystallization buffer Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110081854 | 2011-08-17 | ||
| KR10-2011-0081854 | 2011-08-17 | ||
| PCT/KR2012/006564 WO2013025079A1 (en) | 2011-08-17 | 2012-08-17 | Method for preparing active form of tnfr-fc fusion protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016105574A Division JP2016168049A (ja) | 2011-08-17 | 2016-05-26 | 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521364A JP2014521364A (ja) | 2014-08-28 |
| JP2014521364A5 JP2014521364A5 (enExample) | 2015-10-29 |
| JP6223338B2 true JP6223338B2 (ja) | 2017-11-01 |
Family
ID=47715279
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525943A Expired - Fee Related JP6223338B2 (ja) | 2011-08-17 | 2012-08-17 | 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 |
| JP2016105574A Pending JP2016168049A (ja) | 2011-08-17 | 2016-05-26 | 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016105574A Pending JP2016168049A (ja) | 2011-08-17 | 2016-05-26 | 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9279014B2 (enExample) |
| EP (1) | EP2753634B1 (enExample) |
| JP (2) | JP6223338B2 (enExample) |
| KR (1) | KR101454316B1 (enExample) |
| ES (1) | ES2651483T3 (enExample) |
| WO (1) | WO2013025079A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014009031A2 (pt) | 2011-10-18 | 2017-05-09 | Coherus Biosciences Inc | formulações de etanercept estabilizadas com íons de metais |
| KR101494072B1 (ko) * | 2012-03-12 | 2015-02-17 | 한화케미칼 주식회사 | 변이된 글루타민 합성효소 유전자를 포함하는 벡터 및 이를 이용한 목적 단백질의 생산방법 |
| LT2895188T (lt) | 2012-09-11 | 2018-04-10 | Coherus Biosciences, Inc. | Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| BR112016029157A8 (pt) * | 2014-06-13 | 2021-07-06 | Lupin Ltd | processo para purificar a proteína de fusão tnfr:fc |
| ES2733298T3 (es) | 2014-07-18 | 2019-11-28 | Sandoz Ag | Cuantificación de TNFR2:Fc plegado erróneamente |
| KR102018608B1 (ko) * | 2014-12-31 | 2019-09-06 | 주식회사 엘지화학 | 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법 |
| WO2016149139A1 (en) * | 2015-03-13 | 2016-09-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
| US11952399B2 (en) * | 2018-12-18 | 2024-04-09 | Amgen Inc. | Methods for purifying proteins |
| US12202857B2 (en) | 2020-05-08 | 2025-01-21 | Waters Technologies Corporation | Methods for heat-assisted enzyme digestion |
| US12411064B2 (en) | 2020-05-08 | 2025-09-09 | Waters Technologies Corporation | Methods for heat-assisted enzyme digestion |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20030180287A1 (en) | 2002-02-27 | 2003-09-25 | Immunex Corporation | Polypeptide formulation |
| ATE462716T1 (de) * | 2003-10-24 | 2010-04-15 | Amgen Inc | Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen |
| CA2554929A1 (en) * | 2004-01-30 | 2005-08-18 | Amgen Inc. | Process for purifying proteins |
| BRPI0908270A2 (pt) * | 2008-02-29 | 2019-09-10 | Biogen Idec Inc | proteínas de fusão de imunoglobulinas purificadas e método para a sua purificação |
| CN102675465A (zh) * | 2011-03-09 | 2012-09-19 | 上海赛金生物医药有限公司 | 重组人ⅱ型肿瘤坏死因子受体-抗体融合蛋白的纯化方法 |
| WO2012176158A1 (en) * | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
-
2012
- 2012-08-17 EP EP12823797.1A patent/EP2753634B1/en active Active
- 2012-08-17 US US14/239,216 patent/US9279014B2/en active Active
- 2012-08-17 WO PCT/KR2012/006564 patent/WO2013025079A1/en not_active Ceased
- 2012-08-17 JP JP2014525943A patent/JP6223338B2/ja not_active Expired - Fee Related
- 2012-08-17 ES ES12823797.1T patent/ES2651483T3/es active Active
- 2012-08-17 KR KR1020120090341A patent/KR101454316B1/ko not_active Expired - Fee Related
-
2016
- 2016-05-26 JP JP2016105574A patent/JP2016168049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2651483T3 (es) | 2018-01-26 |
| EP2753634A4 (en) | 2015-05-20 |
| KR101454316B1 (ko) | 2014-10-27 |
| WO2013025079A1 (en) | 2013-02-21 |
| US20140316114A1 (en) | 2014-10-23 |
| JP2014521364A (ja) | 2014-08-28 |
| EP2753634A1 (en) | 2014-07-16 |
| KR20130020644A (ko) | 2013-02-27 |
| EP2753634B1 (en) | 2017-11-01 |
| JP2016168049A (ja) | 2016-09-23 |
| US9279014B2 (en) | 2016-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6223338B2 (ja) | 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法 | |
| JP4363986B2 (ja) | タンパク質の精製方法 | |
| EP3048899B1 (en) | On-column viral inactivation methods | |
| AU2012283858C1 (en) | Polypeptide separation methods | |
| JP2020508968A (ja) | プロテインｌを用いたタンパク質精製 | |
| AU2015214245B2 (en) | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications | |
| RU2698671C2 (ru) | КОЛИЧЕСТВЕННАЯ ОЦЕНКА НЕПРАВИЛЬНО СВЕРНУТОГО TNFR2:Fc | |
| JP2016519144A (ja) | 最小限の単量体の分離を伴う組換えポリクローナル多量体の分離 | |
| JP2019172702A (ja) | 目的とする含量で不純物を含むＴＮＦＲ−Ｆｃ融合タンパク質の製造方法 | |
| EP3870331B1 (en) | Modification of antibody fcrn binding | |
| NZ733388B (en) | Method for preparing tnfr-fc fusion protein containing target content of impurities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150430 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150730 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150831 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20151204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170724 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171003 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6223338 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |